Vaccines And Therapeutics Articles & Analysis: Older
89 news found
By harnessing cutting-edge technology and expertise in vaccine development, Ace Therapeutics aims to provide a novel way to prevent and control the spread of superbugs. ...
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. ...
ByOncoVITA
By accurately detecting these variants, healthcare professionals and researchers can make informed decisions regarding public health measures, treatment options, and vaccine effectiveness. COVID-19 RT-qPCR Detection Kit Plus In addition to the COVID-19 Mutation RT-qPCR Detection Kit Alpha Delta Kappa, Alfa Chemistry has also introduced the COVID-19 RT-qPCR Detection Kit Plus. ...
“I am excited to announce this development and commercialization agreement to explore the potential to utilize our C1 protein production platform to produce high-quality messenger RNA products at lower cost which will be easier to manufacture than in vitro mRNA, making it accessible to everyone, including patients from poorer countries. The global mRNA vaccine and ...
"End-to-End Support for Your Pharmaceutical Journey", with the commitment to researchers, BOC Sciences will attend the renowned World Vaccine Congress Europe in Barcelona, Spain, from 16 to 19 Octobe World Vaccine Congress Europe has become the world's largest and most established meeting dedicated to vaccines. ...
In addition to showing great promise in image-guided cancer therapy, PLGA-based drug delivery systems are widely used for other therapeutic applications such as vaccination or treatment of neurological disorders, inflammation and other diseases. ...
Airfinity announces today the launch of Airfinity IDA (Infectious Disease Analytics) 360, a new platform that will provide a comprehensive overview of vaccine and therapeutics candidates across the full infectious disease landscape. ...
Tony is currently the CEO of Evox Therapeutics, an Oxford-based company developing exosome therapeutics, and has an extensive background in mRNA and more specifically LNPs through his roles at Moderna and Alnylam. ...
ByeTheRNA
Funding from the BARDA Division of Research, Innovation, and Ventures (DRIVe) enabled the company to reformulate LMN-301, previously developed for oral delivery, and to evaluate its potential as an anti-viral therapeutic delivered to the respiratory tract, the primary site of SARS-CoV-2 infection. ...
Creative BioMart, a biotechnology company that offers a wide range of solutions dedicated to helping researchers and pharmaceutical companies discover and develop novel drugs in the treatment of cancer, autoimmune diseases, etc., now offers MHC solutions for cell therapy and vaccine development. According to the official speaker from Creative BioMart, based on MHC-like ...
By doing so we’ll improve our ability to create new biologics from natural proteins, and bring new therapeutics to patients across a wide range of indications from infectious disease vaccines and therapeutics, to rheumatology, to rare disease, and to autoimmune disorders. ...
An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM). ...
The analysis was carried out by researchers at Lund University and provides additional support for the application of the therapeutic diabetes vaccine Diamyd® to prevent or delay clinical type 1 diabetes, and aligns with the rationale of the VINNOVA-financed ASSET project (AI for Sustainable Prevention of Autoimmunity in the Society) coordinated by Diamyd ...
The last patient in the investigator-initiated clinical trial DIAGNODE-B has received its additional injection (“booster”) of the therapeutic diabetes vaccine Diamyd®. The trial includes 6 patients with Type 1 diabetes who earlier participated in the DIAGNODE-1 or DIAGNODE-2 trials and who carry the genetic HLA DR3-DQ2 haplotype. ...
Jake Kurtis, identified the parasite protein PfGARP as a target of human antibodies which kill up to 100% of parasites in vitro by inducing apoptosis or parasite programmed cell death – this discovery forms the basis of Ocean Biomedical’s lipid encapsulated mRNA-based vaccine and therapeutic monoclonal antibodies. Ocean’s breakthrough approach ...
Updated 12-month results from the open-label investigator-initated Phase II clinical trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd® in individuals diagnosed with Latent Autoimmune Diabetes in Adults (LADA) were presented today at the European Association for the Study of Diabetes (EASD) conference in ...
“Through our successful partnership with K2HV, this refinancing and access to additional capital further enables important financial flexibility as we continue our commercial launch of PreHevbrio™ and advance our prophylactic and therapeutic vaccine pipeline,” said Jeff Baxter, VBI’s President and CEO. ...
The RIGHT Fund financially supports R&D projects for vaccines, therapeutics, and diagnostics technology tackling endemic and emerging infectious diseases in LMICs. ...
Ocean Biomedical is accelerating development of a uniquely powerful malaria vaccine and several malaria therapeutics that target newly discovered pathways. ...
An article presenting the 5-month interim results from the open-label trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal Frontiers in Endocrinology. ...